Cellzome, developer of the Kinobeads™ technology, signed a major deal with GlaxoSmithKline for the development of kinase inhibitors to treat inflammatory diseases. Cellzome could receive a total of £830 M (US$1.5 B) if drugs developed for all seven identified targets make it to market.